Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over the age of 21
- People who have a family member, friend, or carer who can give an independent assessment of how they are functioning day-to-day
- People whose primary language is English
- People whose symptoms came on gradually, have been getting worse over time, and who have received a clinical diagnosis of a typical memory-related form of Alzheimer's disease, or an atypical form such as Logopenic Aphasia (a language disorder) or Posterior Cortical Atrophy (a visual and spatial processing disorder)
- People with Logopenic Aphasia whose earliest and most prominent difficulties are with language
- People with typical memory-related Alzheimer's disease whose ability to recall personal past events (such as things that happened to them) is relatively better preserved compared to difficulties in other thinking or cognitive areas
Who may not be able to join:
- People who have had a stroke or brain tumour that could explain their symptoms
- People whose earliest symptom is difficulty recalling personal past events, or who meet the criteria for mild cognitive impairment (a condition partway between normal ageing and dementia) (confirm with trial site)
- People who have a diagnosis of another brain-degenerating condition, including behavioural variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy
- People with very poor vision (vision of 20/400 or worse, even with glasses)
- People who are pregnant, have recently given birth, or are breastfeeding
- People who cannot have a type of brain scan called a tau-PET scan, due to an irregular heart rhythm detected on a heart tracing test (ECG), or who have certain genetic conditions including Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, or Down's syndrome
- People for whom an MRI brain scan is not safe or suitable, such as those with metal implants in the head, a cardiac pacemaker, or severe claustrophobia (fear of enclosed spaces)
- People who have certain structural brain abnormalities, are medically unstable, or are taking medications that may affect brain structure or activity, such as chemotherapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jennifer Whitwell, Ph.D., Mayo Clinic
Phone: 507-284-3863
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).; Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.